NanoCarrier Co., Ltd.

Tokyo Stock Exchange 4571.T

NanoCarrier Co., Ltd. EBT Margin for the year ending March 31, 2024: -573.78%

NanoCarrier Co., Ltd. EBT Margin is -573.78% for the year ending March 31, 2024, a 11.34% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

NanoCarrier Co., Ltd. EBT Margin for the year ending March 31, 2023 was -647.16%, a 9.07% change year over year.
NanoCarrier Co., Ltd. EBT Margin for the year ending March 31, 2022 was -711.68%, a 21.28% change year over year.
NanoCarrier Co., Ltd. EBT Margin for the year ending March 31, 2021 was -904.04%, a -149.20% change year over year.
NanoCarrier Co., Ltd. EBT Margin for the year ending March 31, 2020 was -362.77%, a 0.16% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Tokyo Stock Exchange: 4571.T

NanoCarrier Co., Ltd.

CEO	Dr. Shiro Akinaga Ph.D.
IPO Date	March 5, 2008
Location	Japan
Headquarters	Onoya-Kyobashi Building
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years